Pfizer and biontech initiate a study as part of broad development plan to evaluate covid-19 booster and new vaccine variants

New york and mainz, germany, february 25 , 2021 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the pfizer-biontech covid-19 vaccine (bnt162b2) to understand the effect of a booster on immunity against covid-19 caused by the circulating and potential newly emerging sars-cov-2 variants. the study will draw upon participants from the phase 1 study in the united states who will be offered the opportunity to receive a 30 Μg booster of the current vaccine 6 to 12 months after receiving their initial two-dose regimen. the study is part of the companies' clinical development strategy to determine the effectiveness of a third dose against evolving variants.
BNTX Ratings Summary
BNTX Quant Ranking